RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Royalty Pharma Stock

Royalty Pharma ROA 2024

Royalty Pharma ROA

0.07

Ticker

RPRX

ISIN

GB00BMVP7Y09

WKN

A2P62D

In 2024, Royalty Pharma's return on assets (ROA) was 0.07, a 2,621.26% increase from the 0 ROA in the previous year.

Royalty Pharma Aktienanalyse

What does Royalty Pharma do?

Royalty Pharma PLC is a US-based company specializing in investments in biopharmaceutical companies and their products. The company was founded in 1996 by Pablo Legorreta and is headquartered in New York City. It has subsidiaries in Bermuda, Ireland, Luxembourg, and Switzerland. The business model of Royalty Pharma involves providing financial resources to manufacturers of biopharmaceuticals in exchange for a share in the licenses and sales of their products. This allows Royalty Pharma to participate in the development and commercial exploitation of medications without bearing the risk of developing active substances or obtaining approvals. In recent years, Royalty Pharma has invested in a variety of companies to benefit from their commercial success. Examples of companies they work with include Biomarin Pharmaceuticals, Vertex, Teva Pharmaceutical Industries, and General Electric. Royalty Pharma now has a portfolio of over 45 investments in products from companies such as AbbVie, Gilead, Roche, and Amgen. The range of products includes cancer therapies and vaccines, used for both rare diseases and broader applications. One of the most well-known products in Royalty Pharma's portfolio is the cancer drug Kadcyla from Roche. This medication is used in the treatment of breast cancer and has been successful in slowing tumor growth. Another example is the commercial success of the hepatitis C medication Harvoni from Gilead, which improves the quality of life for affected patients and saves lives. Royalty Pharma also has a financing division that focuses on the purchase of existing or future license fees. This division offers credit agreements for biopharmaceutical companies and serves as a good financing alternative for small and medium-sized enterprises. Overall, Royalty Pharma has a successful track record in investing in the biopharmaceutical industry. The model allows the company to benefit from innovative products and their commercial exploitation without taking on the risk of drug development. This allows the company to continue offering attractive returns to its investors. Royalty Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Royalty Pharma's Return on Assets (ROA)

Royalty Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Royalty Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Royalty Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Royalty Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Royalty Pharma stock

What is the Return on Assets (ROA) of Royalty Pharma this year?

The Return on Assets (ROA) of Royalty Pharma is 0.07 undefined this year.

What was the ROA of Royalty Pharma compared to the previous year?

The ROA of Royalty Pharma has increased by 2,621.26% compared to the previous year.

What consequences do high ROA have for investors of Royalty Pharma?

A high ROA is advantageous for investors of Royalty Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Royalty Pharma?

A low ROA can be unfavorable for investors of Royalty Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Royalty Pharma affect the company?

An increase in ROA of Royalty Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Royalty Pharma impact the company?

A reduction in the ROA of Royalty Pharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Royalty Pharma?

Some factors that can influence the ROA of Royalty Pharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Royalty Pharma important for investors?

The ROA of Royalty Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Royalty Pharma take to improve ROA?

To improve ROA, Royalty Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Royalty Pharma pay?

Over the past 12 months, Royalty Pharma paid a dividend of 0.8 USD . This corresponds to a dividend yield of about 3.21 %. For the coming 12 months, Royalty Pharma is expected to pay a dividend of 0.78 USD.

What is the dividend yield of Royalty Pharma?

The current dividend yield of Royalty Pharma is 3.21 %.

When does Royalty Pharma pay dividends?

Royalty Pharma pays a quarterly dividend. This is distributed in the months of March, June, September, December.

How secure is the dividend of Royalty Pharma?

Royalty Pharma paid dividends every year for the past 10 years.

What is the dividend of Royalty Pharma?

For the upcoming 12 months, dividends amounting to 0.78 USD are expected. This corresponds to a dividend yield of 3.12 %.

In which sector is Royalty Pharma located?

Royalty Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Royalty Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Royalty Pharma from 12/10/2024 amounting to 0.21 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did Royalty Pharma pay the last dividend?

The last dividend was paid out on 12/10/2024.

What was the dividend of Royalty Pharma in the year 2023?

In the year 2023, Royalty Pharma distributed 0.76 USD as dividends.

In which currency does Royalty Pharma pay out the dividend?

The dividends of Royalty Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Royalty Pharma

Our stock analysis for Royalty Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Royalty Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.